Literature DB >> 8486669

The specific association of a phosphofructokinase isoform with myocardial calcium-independent phospholipase A2. Implications for the coordinated regulation of phospholipolysis and glycolysis.

S L Hazen1, R W Gross.   

Abstract

We have demonstrated previously that myocardial cytosolic calcium-independent phospholipase A2 is a 40-kDa polypeptide regulated by ligand-modulated protein-protein interactions (Hazen, S.L., and Gross, R.W. (1991) J. Biol. Chem. 266, 14526-14534). We now demonstrate that an 85-kDa polypeptide which possesses sequence homology to and chemical, physical, immunological, and chromatographic similarities with phosphofructokinase (PFK) specifically interacts with the 40-kDa phospholipase A2 catalytic subunit and represents the putative protein regulatory element identified in previous work. Multiple independent lines of evidence document the association between the 85-kDa phosphofructokinase isoform and the 40-kDa myocardial cytosolic calcium-independent phospholipase A2 catalytic polypeptide, including 1) the coelution of the 85- and 40-kDa polypeptides which migrate as a 400-kDa complex during gel filtration chromatography, 2) the stoichiometry between the 85- and 40-kDa polypeptides which corresponds to a complex comprised of a tetrameric PFK isoform and a 40-kDa phospholipase A2 catalytic polypeptide, 3) the demonstration that the 85-kDa phosphofructokinase isoform acts as a specific and reversible affinity adsorbent for myocardial cytosolic phospholipase A2 catalytic activity, 4) the immunoprecipitation of myocardial cytosolic phospholipase A2 activity utilizing chicken anti-rabbit skeletal muscle PFK IgG, 5) the specific release of phospholipase A2 from ATP-agarose after formation of a ternary complex comprised of allosteric modifiers of phosphofructokinase, and 6) the selective attenuation of the denaturation of purified homogeneous calcium-independent cytosolic phospholipase A2 with PFK. Collectively, these results demonstrate the highly specific association of a phosphofructokinase isoform with myocardial cytosolic calcium-independent phospholipase A2 and suggest a novel biochemical mechanism underlying the coordinated regulation of phospholipolysis and glycolysis previously observed in myocardium and in other mammalian tissues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486669

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Phospholipase A2 and its potential regulation of islet function.

Authors:  E Simonsson; B Ahrén
Journal:  Int J Pancreatol       Date:  2000-02

2.  Calcium-independent phospholipase A2 in isolated rabbit ventricular myocytes.

Authors:  J McHowat; M H Creer
Journal:  Lipids       Date:  1998-12       Impact factor: 1.880

3.  Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A2 (iPLA2) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA2 gene on chromosome 22q13.1.

Authors:  Z Ma; X Wang; W Nowatzke; S Ramanadham; J Turk
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

4.  Intravenously injected [1-14C]arachidonic acid targets phospholipids, and [1-14C]palmitic acid targets neutral lipids in hearts of awake rats.

Authors:  E J Murphy; T A Rosenberger; C B Patrick; S I Rapoport
Journal:  Lipids       Date:  2000-08       Impact factor: 1.880

Review 5.  Calcium-independent phospholipases A2 and their roles in biological processes and diseases.

Authors:  Sasanka Ramanadham; Tomader Ali; Jason W Ashley; Robert N Bone; William D Hancock; Xiaoyong Lei
Journal:  J Lipid Res       Date:  2015-05-28       Impact factor: 5.922

6.  Reversible high affinity inhibition of phosphofructokinase-1 by acyl-CoA: a mechanism integrating glycolytic flux with lipid metabolism.

Authors:  Christopher M Jenkins; Jingyue Yang; Harold F Sims; Richard W Gross
Journal:  J Biol Chem       Date:  2011-01-23       Impact factor: 5.157

Review 7.  Phospholipase A2-mediated hydrolysis of cardiac phospholipids: the use of molecular and transgenic techniques.

Authors:  L J De Windt; R S Reneman; G J Van der Vusse; M Van Bilsen
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

8.  Cytosolic phospholipase A2 alpha inhibition prevents neuronal NMDA receptor-stimulated arachidonic acid mobilization and prostaglandin production but not subsequent cell death.

Authors:  Ava L Taylor; Joseph V Bonventre; Tracy F Uliasz; James A Hewett; Sandra J Hewett
Journal:  J Neurochem       Date:  2008-06-28       Impact factor: 5.372

Review 9.  Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction.

Authors:  Ari Cedars; Christopher M Jenkins; David J Mancuso; Richard W Gross
Journal:  J Cardiovasc Pharmacol       Date:  2009-04       Impact factor: 3.105

10.  Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases.

Authors:  Federica Sotgia; Gloria Bonuccelli; Carlo Minetti; Scott E Woodman; Franco Capozza; Robert G Kemp; Philipp E Scherer; Michael P Lisanti
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.